Synthetic Receptors Rewired to Sense Amyloid Beta and Release Therapeutics in the Lab

Scientists have compared three synthetic receptor platforms designed to detect amyloid beta, the protein at the heart of Alzheimer’s disease pathology, and to switch on the production of therapeutic molecules only when the target is present. The study, published in Alzheimer’s Research & Therapy, tested T cells Redirected for Universal Cytokine Killing (TRUCKs), synthetic Notch (synNotch) receptors, and Synthetic Intramembrane Proteolysis Receptors (SNIPRs) side by side in laboratory cell cultures.

These systems build on chimeric antigen receptors, or CARs, which were originally developed in cancer immunotherapy to steer immune cells toward tumor cells. Researchers are now adapting the same logic to Alzheimer’s disease, directing cytokine secretion and phagocytosis by immune and glial cells toward amyloid beta pathology. The newer synthetic receptors go a step further: rather than simply activating a cell, they allow it to deliver genetically encoded therapeutics in response to a specific molecular cue.

To make the comparison as rigorous as possible, the team gave every receptor the same amyloid beta-targeting binding domain, one derived from the antibody Aducanumab. Each receptor was then wired to identical inducible expression cassettes driving two transgenes: a secreted Metridia luciferase reporter, which made output easy to measure, and a chimeric human-mouse antibody based on Lecanemab, another amyloid beta-directed therapy.

The experiments were carried out in Jurkat cells, a widely used human T cell line, and in human regulatory T cells, known as Tregs. To mimic Alzheimer’s disease pathology in the dish, the engineered cell clones were exposed to oligomer-enriched amyloid beta preparations. In the Jurkat cells, the researchers assessed all three receptor systems for basal transcriptional leakage, ligand-independent activation, and ligand-dependent activation, using flow cytometry and luciferase reporter assays. The production of the Lecanemab-based antibody by the synNotch and SNIPR systems was further evaluated in both Jurkat cells and human Tregs using immunofluorescence.

The results split cleanly into two camps. The inducible expression cassettes of all three receptor systems showed some degree of transcriptional leakage, meaning they produced low levels of output even without their intended trigger. But the TRUCK variants failed a more demanding test: despite confirmed CAR function and demonstrated transcriptional competence of 6xNFAT response elements paired with different minimal promoters, none of the TRUCK designs produced output in response to oligomer-enriched amyloid beta that rose significantly above that basal leakage.

In contrast, the synNotch and SNIPR receptors responded robustly to amyloid beta oligomers. Expressed in both Jurkat cells and human Tregs, these two platforms supported amyloid beta-dependent inducible transgene expression, triggering the production of the reporter and the antibody payload when the pathology-mimicking target was present.

The authors emphasize that the modular architecture of these receptors is a key practical advantage. Because the payload gene sits downstream of the sensing module, the Lecanemab-based antibody used in this proof-of-concept work could be swapped for alternative therapeutic payloads while preserving the amyloid beta-dependent delivery mechanism.

A second advantage is orthogonality. The receptor sequences described in the paper can, according to the authors, be used across different model species and cell types in further studies without requiring receptor redesign. That could lower the barrier for other laboratories wanting to build on the approach, since the same genetic parts would not need to be re-engineered for each new context.

It is important to keep the scope of this work in view. Everything reported here was done in vitro, in engineered cell lines and human regulatory T cells exposed to amyloid beta preparations in culture. The study demonstrates that Aβ-targeting SNIPR and synNotch systems can support amyloid beta-dependent inducible transgene expression under laboratory conditions; it does not establish safety or efficacy in patients or in animal models of Alzheimer’s disease. The authors themselves frame the work as a demonstration of feasibility and a resource for further studies, noting that the provided sequences can support follow-up experiments across model species and cell types.

Even so, the head-to-head design offers a useful lesson for the broader field of cell-based therapeutics for neurodegenerative disease. As oncology-derived synthetic biology continues to be adapted for Alzheimer’s disease, the choice of receptor platform appears to matter: in this comparison, two of the three systems delivered programmable, target-dependent gene expression, while the third did not rise above its own background noise. For researchers hoping to program cells to sense amyloid beta and respond with tailored therapeutic payloads, the results point toward synNotch and SNIPR architectures as the more promising starting points.

Subject of Research: In vitro comparison of amyloid beta-targeting synthetic receptor platforms for inducible transgene expression

Article Title: In vitro comparison of Aβ-targeting SNIPR, synNotch, and TRUCK for programmable transgene expression

Article References: Siebrand, C. J., Mayeri, Z., Brown, I., Andersen, J. K., & Walton, C. C. (2026). In vitro comparison of Aβ-targeting SNIPR, synNotch, and TRUCK for programmable transgene expression. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-026-02237-8

Image Credits: AI Generated

DOI: 10.1186/s13195-026-02237-8

Keywords: Alzheimer's disease, amyloid beta, synthetic receptors, SNIPR, synNotch, TRUCK, CAR, chimeric antigen receptors, regulatory T cells, transgene expression, Aducanumab, Lecanemab